Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36511784
2.
Intrinsically disordered regions of the Msn2 transcription factor encode multiple functions using interwoven sequence grammars.
Nucleic Acids Res
; 52(5): 2260-2272, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38109289
3.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268449
4.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol
; 20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088119
5.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810754
6.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731259
7.
Zanubrutinib in Chronic Lymphocytic Leukemia. Reply.
N Engl J Med
; 388(18): 1720-1721, 2023 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37133597
8.
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
Haematologica
; 106(9): 2354-2363, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054121
9.
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Future Oncol
; 16(10): 517-523, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32207333
10.
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database.
Haematologica
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426293
11.
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Future Oncol
; 14(22): 2229-2237, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29869556
12.
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
Blood Adv
; 8(10): 2478-2490, 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38502198
13.
Changes in positive and negative affect in psychotherapy for depression and anxiety.
J Consult Clin Psychol
; 92(4): 249-259, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127575
14.
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Blood Adv
; 8(7): 1639-1650, 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38315878
15.
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
Br J Haematol
; 162(2): 250-62, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23682827
16.
A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 12(8): 832-838, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37145975
17.
Positive affect treatment targets reward sensitivity: A randomized controlled trial.
J Consult Clin Psychol
; 91(6): 350-366, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892884
18.
Longitudinal associations among dimensional symptoms of depression and anxiety and first onset suicidal ideation in adolescents.
Suicide Life Threat Behav
; 53(3): 457-469, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36942926
19.
Personality predicts pre-COVID-19 to COVID-19 trajectories of transdiagnostic anxiety and depression symptoms.
J Psychopathol Clin Sci
; 132(6): 645-656, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37261781
20.
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Lancet Haematol
; 10(1): e35-e45, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400069